Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.54 |
| ▸ | ACE | P12821 | 4/20 | 0.54 |
| ▸ | CPA1 | P15085 | 4/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24084101 | 0.89 | TRPA1 (0.49) | MMEACECPA1ACE2TRPA1 | |
| SCHEMBL7379335 | 0.84 | MME (0.70) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL9068541 | 0.84 | MME (0.70) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL4087621 | 0.83 | MME (0.54) | MMEL3MBTL1NPSR1NAALAD2CYP1A2 | |
| SCHEMBL1938079 | 0.83 | MME (0.61) | MMEACECPA1ACE2 | |
| SCHEMBL995916 | 0.83 | MME (0.56) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL28782920 | 0.82 | CSNK1E (0.52) | MMEMMP2 | |
| SCHEMBL123574 | 0.81 | MME (0.58) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL15592756 | 0.81 | MME (0.58) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL2781126 | 0.81 | MME (0.58) | MMEACECPA1ACE2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| EP-1858840-A2 | ANALOGS OF 4-HYDROXYISOLEUCINE AND USES THEREOF | Innodia Inc. (CA) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007107008-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF DISORDERS OF FAT METABOLISM AND OBESITY | INNODIA INC. (CA) | 2007-09-27 | — | — | WO | disclosed |
| WO-2006120574-A2 | ANALOGS OF 4-HYDROXYISOLEUCINE AND USES THEREOF | INNODIA INC. (CA) | 2006-11-16 | — | — | WO | disclosed |
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | INVESTISSEMENT QUEBEC (CA) | 2006-10-05 | — | — | US | disclosed |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | UNIVERSITE LOUIS PASTEUR STRASBOURG I (FR) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | GPR119, HSD3B1, PC | MME 2026/4885ACE 376/4885CPA1 842/4885 |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | GPR119, SLC2A1, SLC5A1 | MME 3197/4885ACE 1110/4885CPA1 966/4885 |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | LIPC, PC, LIPE | MME 2323/4885ACE 1014/4885CPA1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.